Search for: "Novartis Pharmaceuticals Corporation"
Results 101 - 120
of 216
Sort by Relevance
|
Sort by Date
22 Dec 2011, 11:59 am
Novartis Pharmaceuticals Corp., 793 F. [read post]
16 Dec 2011, 9:15 pm
IBC Legal will be holding its 20th annual Biotech & Pharmaceutical Patenting conference on February 21-22, 2012 in Munich, Germany. [read post]
25 Nov 2011, 5:00 am
Novartis Pharmaceuticals Corp., 2011 WL 5835414, slip op. [read post]
19 Nov 2011, 5:55 am
The same jury noted that the Pharmaceuticals Company had discriminated against its female employees for over a decade. [read post]
4 Nov 2011, 4:09 am
Novartis Pharmaceutical paid $422.5 million to settle claims it promoted its epilepsy drug, Trileptal, for off label uses. [read post]
8 Sep 2011, 11:04 am
.; RECLAST (zoledronic acid) injection, Novartis Pharmaceuticals Corporation; and, the generic equivalents for these products, if any. [read post]
27 Aug 2011, 7:55 pm
This is "the sport of kings," that only large corporations can play. [read post]
11 Aug 2011, 4:43 am
NOVARTIS PHARMACEUTICALS CORPORATION, App. [read post]
27 Jul 2011, 1:01 am
Highlights this week included: Corporate self-interest and strategic choices: Gilead licenses to Medicines Patent Pool (IP Watch) (KEI) Glybera (Alipogene tiparvovec) – EU: EMA continues to defer approval of first gene therapy application in Europe (Patent Docs) Cenestin (Synthetic conjugated estrogens) – US: CAFC: Prosecution history estoppel bars Duramed’s allegations of infringement under doctrine of equivalents: Duramed Pharmaceuticals, Inc. v. [read post]
24 Jul 2011, 1:21 pm
See In re Novartis, 611 F.3d at 154. [read post]
11 Jul 2011, 4:47 pm
Kudos to The RPM Report team, which took note of some statements made during a recent meeting of FDA’s Arthritis Drugs Advisory Committee to discuss Novartis Pharmaceuticals Corporation’s (“Novartis’”) supplemental Biologics License Application (“sBLA”) for ILARIS (canakinumab) for the treatment of gouty arthritis attacks in certain patients. [read post]
6 Jul 2011, 2:21 am
(Patent Baristas) US: FDA’s Chief Counsel, Ralph Tyler, set to leave FDA (FDA Law Blog) US: Docs at BIO: Steve Burrill’s state of the biotechnology industry report 2011 (Patent Docs) US: Counterfeiting: White House IP Czar Victoria Espinel on working with corporations (BIOtechNOW) US: Banning gene patents will promote innovation? [read post]
30 May 2011, 7:34 am
Novartis Pharmaceuticals Corp., No. 06-Civ-260 (BMC) (EDNY), and we’ve got some good news to report. [read post]
19 May 2011, 1:15 pm
Novartis Pharmaceuticals Corp., ___ F. [read post]
18 Apr 2011, 5:51 pm
Prior to joining HP&M, Linda served in several pharmaceutical industry positions, including as Senior Director, Global Regulatory Policy and Intelligence, Janssen Pharmaceutical Companies of Johnson & Johnson, Executive Director, FDA Liaison, Drug Regulatory Affairs, Novartis Pharmaceuticals Corporation, and Director, Global Regulatory Affairs, Legislative Policy and Regulatory Liaison, Pharmacia Corporation. [read post]
26 Mar 2011, 10:17 am
It is another in a spate of gender discrimination lawsuits filed recently against large corporations: last Monday a class action lawsuit was filed against Bayer HealthCare Pharmaceuticals and its parent, Bayer Corp., both U.S. units of Bayer AG, alleging the company has engaged in various discriminatory behaviors against its female employees. (1) The lawsuit, filed in U.S. [read post]
23 Mar 2011, 1:30 pm
Additional support for this research was provided by the NIH National Center for Research Resources and Novartis Pharmaceuticals Corporation. [read post]
15 Mar 2011, 1:31 pm
Novartis Pharmaceuticals Corp., 2011 U.S. [read post]
1 Mar 2011, 4:09 am
Novartis Pharmaceuticals Corp. v. [read post]
17 Feb 2011, 1:59 pm
SmithKline Beecham Corporation (“Glaxo”) hired plaintiffs in 2003 to meet with physicians and encourage them to prescribe Glaxo pharmaceuticals. [read post]
